Vishal Doshi

As the Founder and CEO of AUM Biosciences, I bring proven expertise in structuring and executing multi-billion dollar deals worth over $6 billion in global drug development. My track record includes a $145M private equity deal that contributed to bringing 3 major oncology blockbusters to market with combined peak sales exceeding $4B annually, including Lenvima and Eribulin.

I successfully transitioned AUM from pre-clinical to clinical stage within 12 months, earning the 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year award from Frost & Sullivan and recognition as a Young Global Leader by the World Economic Forum. With a Master%27s in Pharmaceutical Sciences focused on cancer therapeutics and senior business development experience at IQVIA, EPS International, and ICON, I offer deep scientific knowledge combined with commercial acumen.

As a Key Opinion Leader to the Korean Health Industry Development Institute, I excel at cross-border strategy and global expansion. Companies that benefit most from my expertise are biotech and pharmaceutical organizations seeking to scale globally, navigate complex deal structures, advance oncology pipelines, and those requiring strategic guidance on clinical development, regulatory pathways, and international market entry in the Asia-Pacific region.